Search hospitals > Oklahoma > Tulsa
Oklahoma Cancer Specialists and Research Institute-Tulsa
Claim this profileTulsa, Oklahoma 74146
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Ovarian Cancer
Conducts research for Adenocarcinoma
Conducts research for Fallopian Tube Cancer
257 reported clinical trials
27 medical researchers
Summary
Oklahoma Cancer Specialists and Research Institute-Tulsa is a medical facility located in Tulsa, Oklahoma. This center is recognized for care of Cancer, Recurrence, Ovarian Cancer, Adenocarcinoma, Fallopian Tube Cancer and other specialties. Oklahoma Cancer Specialists and Research Institute-Tulsa is involved with conducting 257 clinical trials across 440 conditions. There are 27 research doctors associated with this hospital, such as Debra L. Richardson, Kathleen Moore, M.D., MS, Raid Aljumaily, and Wajeeha Razaq, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Recurrence
Global LeaderStage IV
Stage III
BRCA1 positive
Top PIs
Debra L. RichardsonUniversity of Oklahoma Health Sciences Center2 years of reported clinical research
Expert in Ovarian Cancer
Expert in Cancer
32 reported clinical trials
51 drugs studied
Kathleen Moore, M.D., MSUniversity of Oklahoma Health Sciences Center1 year of reported clinical research
Expert in Ovarian Cancer
Expert in Ovarian Tumors
29 reported clinical trials
81 drugs studied
Raid AljumailyUniversity of Oklahoma Health Sciences Center7 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
24 reported clinical trials
40 drugs studied
Wajeeha Razaq, MDUniversity of Oklahoma Health Sciences Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
24 reported clinical trials
46 drugs studied
Clinical Trials running at Oklahoma Cancer Specialists and Research Institute-Tulsa
Bladder Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Ovarian Cancer
Cancer
Renal Cell Carcinoma
Lung Cancer
Colorectal Cancer
Endometrial Cancer
TROP2 ADC
for Cancer
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma
Recruiting1 award Phase 1 & 213 criteria
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of bladder cancer patients who have undergone surgical removal of their bladder.
Recruiting1 award Phase 2 & 310 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Oklahoma Cancer Specialists and Research Institute-Tulsa?
Oklahoma Cancer Specialists and Research Institute-Tulsa is a medical facility located in Tulsa, Oklahoma. This center is recognized for care of Cancer, Recurrence, Ovarian Cancer, Adenocarcinoma, Fallopian Tube Cancer and other specialties. Oklahoma Cancer Specialists and Research Institute-Tulsa is involved with conducting 257 clinical trials across 440 conditions. There are 27 research doctors associated with this hospital, such as Debra L. Richardson, Kathleen Moore, M.D., MS, Raid Aljumaily, and Wajeeha Razaq, MD.